These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 19790234)

  • 1. Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels.
    Liu X; Gomez-Pinillos A; Liu X; Johnson EM; Ferrari AC
    Prostate; 2010 Feb; 70(2):179-89. PubMed ID: 19790234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line.
    Wang LG; Ossowski L; Ferrari AC
    Oncogene; 2004 Jul; 23(30):5175-84. PubMed ID: 15156193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
    Quéro L; Giocanti N; Hennequin C; Favaudon V
    Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor overexpression in prostate cancer linked to Pur alpha loss from a novel repressor complex.
    Wang LG; Johnson EM; Kinoshita Y; Babb JS; Buckley MT; Liebes LF; Melamed J; Liu XM; Kurek R; Ossowski L; Ferrari AC
    Cancer Res; 2008 Apr; 68(8):2678-88. PubMed ID: 18413735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
    Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
    Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
    Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.
    Gravina GL; Marampon F; Di Staso M; Bonfili P; Vitturini A; Jannini EA; Pestell RG; Tombolini V; Festuccia C
    Prostate; 2010 Aug; 70(11):1166-78. PubMed ID: 20333699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10.
    Ishikura N; Kawata H; Nishimoto A; Nakamura R; Ishii N; Aoki Y
    Prostate; 2010 Apr; 70(5):457-66. PubMed ID: 19902465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells.
    Church DR; Lee E; Thompson TA; Basu HS; Ripple MO; Ariazi EA; Wilding G
    Prostate; 2005 May; 63(2):155-68. PubMed ID: 15486991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
    Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
    Hodgson MC; Astapova I; Hollenberg AN; Balk SP
    Cancer Res; 2007 Sep; 67(17):8388-95. PubMed ID: 17804755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S; Agoulnik IU; Weigel NL
    Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
    Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
    Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
    Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
    Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased resistance to trail-induced apoptosis in prostate cancer cells selected in the presence of bicalutamide.
    Mitterberger M; Neuwirt H; Cavarretta IT; Hobisch A; Culig Z
    Prostate; 2007 Aug; 67(11):1194-201. PubMed ID: 17520660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells.
    Hara T; Kouno J; Nakamura K; Kusaka M; Yamaoka M
    Prostate; 2005 Nov; 65(3):268-75. PubMed ID: 16015592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
    Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
    Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide.
    Hobisch A; Fritzer A; Comuzzi B; Fiechtl M; Malinowska K; Steiner H; Bartsch G; Culig Z
    Prostate; 2006 Mar; 66(4):413-20. PubMed ID: 16302272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide.
    Madarová J; Lukesová M; Hlobilková A; Riháková P; Murray PG; Student V; Vojtsek B; Kolár Z
    Neoplasma; 2001; 48(5):419-24. PubMed ID: 11845989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor-mediated repression of novel target genes.
    Prescott J; Jariwala U; Jia L; Cogan JP; Barski A; Pregizer S; Shen HC; Arasheben A; Neilson JJ; Frenkel B; Coetzee GA
    Prostate; 2007 Sep; 67(13):1371-83. PubMed ID: 17624924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.